HW
ALXN

Hancock Whitney’s Alexion Pharmaceuticals ALXN Stock Holding History

Hancock Whitney’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,131
Closed -$230K – 910
2019
Q4 		$230K Sell
2,131
-1,183
-36% -$127K 0.01% 741
2019
Q3 		$325K Sell
3,314
-161
-5% -$18.1K 0.01% 678
2019
Q2 		$455K Sell
3,475
-610
-15% -$78.6K 0.01% 634
2019
Q1 		$552K Sell
4,085
-228
-5% -$28.4K 0.02% 599
2018
Q4 		$420K Sell
4,313
-586
-12% -$69.3K 0.01% 637
2018
Q3 		$681K Buy
+4,899
New +$615K 0.02% 572

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Hancock Whitney's ALXN Position: Q1 2020 in Review

Hancock Whitney sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 2,131 shares — an estimated $230K sold.

Hancock Whitney first reported a position in ALXN in Q3 2018 and held it in 6 quarters. The position peaked at $681K in Q3 2018. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Hancock Whitney reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Hancock Whitney sold 2,131 Alexion Pharmaceuticals shares in Q1 2020, an estimated $230K.
  • Hancock Whitney first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 6 quarters.
  • Hancock Whitney's Alexion Pharmaceuticals position peaked at $681K in Q3 2018.
  • 654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Hancock Whitney's 13F filing for Q1 2020, filed 8 May 2020.